Equillium, Inc. (EQ)
NASDAQ: EQ · Real-Time Price · USD
1.510
0.00 (0.00%)
Feb 4, 2026, 4:00 PM EST - Market closed
Equillium Employees
Equillium had 35 employees as of December 31, 2024. The number of employees decreased by 9 or -20.45% compared to the previous year.
Employees
35
Change
-9
Growth
-20.45%
Revenue / Employee
$125,486
Profits / Employee
-$697,629
Market Cap
91.95M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 35 | -9 | -20.45% |
| Sep 30, 2024 | 45 | 0 | - |
| Jun 30, 2024 | 45 | -2 | -4.26% |
| Mar 31, 2024 | 44 | 7 | 18.92% |
| Dec 31, 2023 | 44 | 8 | 22.22% |
| Sep 30, 2023 | 45 | 0 | - |
| Jun 30, 2023 | 47 | 2 | 4.44% |
| Mar 31, 2023 | 37 | -10 | -21.28% |
| Dec 31, 2022 | 36 | -9 | -20.00% |
| Sep 30, 2022 | 45 | 0 | - |
| Jun 30, 2022 | 45 | - | - |
| Mar 31, 2022 | 47 | 16 | 51.61% |
| Dec 31, 2021 | 45 | 14 | 45.16% |
| Dec 31, 2020 | 31 | 15 | 93.75% |
| Sep 30, 2020 | 26 | 10 | 62.50% |
| Jun 30, 2020 | 22 | 6 | 37.50% |
| Mar 31, 2020 | 22 | 7 | 46.67% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Agenus | 316 |
| Champions Oncology | 213 |
| Fortress Biotech | 101 |
| Precision BioSciences | 67 |
| aTyr Pharma | 65 |
| Pyxis Oncology | 44 |
| eXoZymes | 31 |
| Cassava Sciences | 30 |
EQ News
- 2 days ago - Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Equillium to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Equillium Reports Third Quarter 2025 Financial Results and Provides Operational Update - GlobeNewsWire
- 3 months ago - Equillium, Inc. (EQ) Discusses Aryl Hydrocarbon Receptor as a Drug Target and EQ504 Program in Immune-Mediated Diseases Transcript - Seeking Alpha
- 3 months ago - Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025 - GlobeNewsWire
- 4 months ago - Equillium Announces Leadership and Corporate Updates - GlobeNewsWire
- 4 months ago - NeuraClick Welcomes Biotech Veteran Daniel M. Bradbury as Strategic and Metabolic Programs Advisor - GlobeNewsWire
- 5 months ago - Equillium to Participate in the Cantor Global Healthcare Conference 2025 - Business Wire